Wave Life Sciences (WVE) Non-Current Debt (2016 - 2018)
Wave Life Sciences' (WVE) quarterly Non-Current Debt came in at $9.2 million in Q4 2018, up 198.87% YoY from $3.1 million in Q4 2017, and up 12.37% on a QoQ basis from $8.2 million in Q3 2018.
Wave Life Sciences (WVE) Non-Current Debt (2016 - 2018) Analysis & Trends
Wave Life Sciences (WVE) has 3 years of Non-Current Debt data on file, last reported at $9.2 million in Q4 2018.
- Quarterly Non-Current Debt rose 198.87% year-over-year to $9.2 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $9.2 million (up 198.87% YoY) and the FY2018 annual result came in at $9.2 million, up 198.87% from the prior year.
- Non-Current Debt advanced to $9.2 million in Q4 2018, from $8.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $9.2 million in Q4 2018 to a low of $116000.0 in Q4 2016.
- A 3-year average of $4.1 million and a median of $3.1 million in 2017 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2017 — Non-Current Debt jumped 2567.24% — and 2018, when it surged 194.67%.
- Tracing WVE's Non-Current Debt over 3 years: stood at $116000.0 in 2016, then jumped by 2567.24% to $3.1 million in 2017, then soared by 198.87% to $9.2 million in 2018.
- The last three Non-Current Debt figures came in at $9.2 million (Q4 2018), $8.2 million (Q3 2018), and $6.5 million (Q2 2018), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 9.25 Mn |
| Sep 30, 2018 | 8.23 Mn |
| Jun 30, 2018 | 6.47 Mn |
| Mar 31, 2018 | 4.19 Mn |
| Dec 31, 2017 | 3.09 Mn |
| Sep 30, 2017 | 2.09 Mn |
| Jun 30, 2017 | 2.20 Mn |
| Mar 31, 2017 | 1.08 Mn |
| Dec 31, 2016 | 116,000.00 |